Pharmaceutical Technology's In the Lab eNewsletter
Taconic Biosciences, a provider of genetically engineered rodent model solutions, sent mice into space to advance research on new therapies for aging-related disease processes.
On Jan. 17, 2019, Taconic Biosciences, a provider of genetically engineered rodent model solutions, announced the completion of a recent mission to the International Space Station (ISS) to advance research on new therapies for aging-related disease processes.
The Rodent Research 8 mission, also referred to as Rodent Research Reference mission 1, studies the microgravity effects on groups of the company’s young and old BALB/cAnTac mice flown on the same mission. Information gathered from this project will serve as control data for past and future missions.
The company reports that previous spaceflight studies demonstrated that mice undergo rapid loss of muscle and bone mass, resembling accelerated aging. Therefore, mice exposed to microgravity via spaceflight are a valuable model to understand and develop new therapies for aging-related immune, bone, and muscle disease processes.
“Participation in the Rodent Research missions is both exciting and inspiring, as the research advances our understanding of how microgravity conditions impact mammalian biology,” said Dr. Gretchen Kusek, associate director of scientific services with Taconic Biosciences, in a company press release. “Over a year of planning and effort goes into preparing animal cohorts to ensure all animals are within the mission specs at the time of launch, so seeing the project through to completion is very rewarding.”
This project is collaboration between the ISS National Lab, National Aeronautics and Space Administration, Bioserve Space Technologies with support from the Leidos Corporation, and Taconic. In September 2018, ISS National Lab issued a request for proposal for investigators to access the information generated from this study. Those selected will receive funding to carry out additional research.
Source: Taconic Biosciences
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.